<DOC>
	<DOCNO>NCT00117897</DOCNO>
	<brief_summary>This multicenter , open-label , randomize , parallel study design evaluate whether single fixed-dose subcutaneous ( SC ) administration pegfilgrastim daily administration Filgrastim absolute neutrophil count ( ANC ) support would assist allow plan dose-on-time ( PDOT ) cyclophosphamide , doxorubicin , vincristine , prednisolone ( CHOP ) chemotherapy Rituximab every 14 day subject aggressive B-cell Non-Hodgkin 's Lymphoma reduce duration neutropenia incidence febrile neutropenia .</brief_summary>
	<brief_title>Treatment Subjects With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically proven aggressive Bcell NonHodgkin 's lymphoma ( IWF classification DH ) : Bone marrow involvement le 30 % demonstrated aspiration Ageadjusted International Prognostic Index ( IPI ) 02 Measurable evaluable disease ECOG performance status 02 Life expectancy great equal 12 week Absolute neutrophil count great 1.5 x 109/L Platelet count great 100 x 109/L Adequate organ function ( serum creatinine less equal 2.0 mg/dL , SGOT/AST SGPT/ALT le 3 x upper limit normal , hemoglobin great equal 10g/dL total serum bilirubin less equal 1.5 mg/dL ) Left Ventricular Ejection Fraction ( LVEF ) great equal 50 % rest MUGA echocardiogram Previously untreated chemotherapy radiotherapy Before study specific procedure study medication administer , subject give write informed consent participation study Burkitt 's Blymphoblastic lymphoma CNS involvement Active infection require treatment systemic ( intravenous oral ) antiinfectives ( antibiotic , antifungal , antiviral ) within 72 hour chemotherapy Use antihypertensives within 12 hour start chemotherapy Known HIV infection Any premalignant myeloid condition malignancy myeloid characteristic ( e.g. , myelodysplastic syndrome , acute chronic myelogenous leukaemia ) Prior malignancy within last 5 year , exception surgically cure basal cell carcinoma , squamous skin cell carcinoma , situ carcinoma cervix Prior bone marrow stem cell transplantation History impair cardiac status , e.g . severe heart disease , cardiomyopathy , congestive heart failure Major surgery within 2 week prior randomization Subject evidently pregnant ( e.g. , positive HCG test unless termination proven ) breast feed Subject use adequate contraceptive precaution Known hypersensitivity E coliderived product ( e.g. , Filgrastim , HUMULIN® Insulin , LAsparaginase , HUMATROPE® Growth Hormone , INTRON A® ) Any psychiatric , addictive kind disorder compromise ability subject give write informed consent and/or comply study protocol procedure Prior exposure pegfilgrastim Subject currently enrol , yet complete least 30 day since end investigational device drug trial ( ) receive investigational agent ( ) Subject previously enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>R-CHOP-14</keyword>
	<keyword>pegfilgrastim</keyword>
	<keyword>neutropenia , clinical trial</keyword>
	<keyword>haematopoietic growth factor</keyword>
</DOC>